Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Non-Current Assets (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Non-Current Assets for 4 consecutive years, with $100.8 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets rose 20.84% to $100.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $409.9 million through Dec 2025, up 21.92% year-over-year, with the annual reading at $100.8 million for FY2025, 20.84% up from the prior year.
  • Non-Current Assets hit $100.8 million in Q4 2025 for Axsome Therapeutics, down from $103.9 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $103.9 million in Q3 2025 to a low of $1.7 million in Q1 2022.
  • Historically, Non-Current Assets has averaged $84.2 million across 4 years, with a median of $85.5 million in 2022.
  • Biggest five-year swings in Non-Current Assets: skyrocketed 4796.74% in 2023 and later dropped 7.58% in 2024.
  • Year by year, Non-Current Assets stood at $85.8 million in 2022, then fell by 2.17% to $84.0 million in 2023, then decreased by 0.64% to $83.4 million in 2024, then grew by 20.84% to $100.8 million in 2025.
  • Business Quant data shows Non-Current Assets for AXSM at $100.8 million in Q4 2025, $103.9 million in Q3 2025, and $103.2 million in Q2 2025.